Cyclic Nucleotide Signaling in Phage Defense and Counter-Defense

Annu Rev Virol. 2022 Sep 29;9(1):451-468. doi: 10.1146/annurev-virology-100120-010228. Epub 2022 May 13.

Abstract

Advances in our understanding of prokaryotic antiphage defense mechanisms in the past few years have revealed a multitude of new cyclic nucleotide signaling molecules that play a crucial role in switching infected cells into an antiviral state. Defense pathways including type III CRISPR (clustered regularly interspaced palindromic repeats), CBASS (cyclic nucleotide-based antiphage signaling system), PYCSAR (pyrimidine cyclase system for antiphage resistance), and Thoeris all use cyclic nucleotides as second messengers to activate a diverse range of effector proteins. These effectors typically degrade or disrupt key cellular components such as nucleic acids, membranes, or metabolites, slowing down viral replication kinetics at great cost to the infected cell. Mechanisms to manipulate the levels of cyclic nucleotides are employed by cells to regulate defense pathways and by viruses to subvert them. Here we review the discovery and mechanism of the key pathways, signaling molecules and effectors, parallels and differences between the systems, open questions, and prospects for future research in this area.

Keywords: CBASS; CRISPR; abortive infection; antiviral defense; cyclic nucleotide.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents
  • Bacteriophages* / genetics
  • CRISPR-Cas Systems
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • Nucleic Acids*
  • Nucleotides, Cyclic
  • Pyrimidines

Substances

  • Antiviral Agents
  • Nucleic Acids
  • Nucleotides, Cyclic
  • Pyrimidines